RRx-001 is the most clinically advanced of the current NLRP3 inflammasome inhibitors in terms of human testing studies and safety, having been safely evaluated in over 300 comorbid, treatment-resistant cancer patients in 12 clinical trials, including in an ongoing phase 3 trial for the treatment of small cell lung cancer (SCLC) (REPLATINUM; NCT03699956) [38]. The gene discussed is NLRP3; the disease is small cell lung carcinoma.